Barclays PLC Has $281,000 Position in ProKidney Corp. (NASDAQ:PROK)

Barclays PLC grew its position in shares of ProKidney Corp. (NASDAQ:PROK) by 575.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,321 shares of the company’s stock after purchasing an additional 124,667 shares during the quarter. Barclays PLC owned approximately 0.05% of ProKidney worth $281,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Bank of New York Mellon Corp raised its holdings in ProKidney by 44.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 179,236 shares of the company’s stock valued at $441,000 after buying an additional 55,266 shares during the last quarter. Rhumbline Advisers increased its position in ProKidney by 8.8% in the 2nd quarter. Rhumbline Advisers now owns 76,190 shares of the company’s stock valued at $187,000 after acquiring an additional 6,181 shares during the period. Marshall Wace LLP bought a new position in shares of ProKidney during the second quarter valued at $124,000. AQR Capital Management LLC acquired a new position in shares of ProKidney during the second quarter worth $50,000. Finally, The Manufacturers Life Insurance Company acquired a new position in shares of ProKidney during the second quarter worth $60,000. 51.59% of the stock is owned by institutional investors and hedge funds.

ProKidney Stock Performance

NASDAQ:PROK opened at $1.66 on Tuesday. The company has a market capitalization of $484.16 million, a PE ratio of -3.02 and a beta of 1.32. ProKidney Corp. has a fifty-two week low of $1.18 and a fifty-two week high of $4.44. The company has a 50 day simple moving average of $1.80 and a two-hundred day simple moving average of $1.99.

ProKidney (NASDAQ:PROK) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.14) earnings per share for the quarter, hitting the consensus estimate of ($0.14). Research analysts predict that ProKidney Corp. will post -0.57 EPS for the current year.

Wall Street Analyst Weigh In

Separately, JPMorgan Chase & Co. assumed coverage on ProKidney in a report on Monday, September 30th. They issued a “neutral” rating for the company. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $4.50.

ProKidney Company Profile

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease.